The most common side effects were nausea, diarrhea, and fatigue
Small cellular changes begin to show results over 30 days
Like many research compounds, responses observed during studies may vary depending on the experimental model and research conditions
Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion
For a full breakdown of how the medication works, its side effects, and what it costs, see our Contrave article
A double-blind, placebo-controlled, clinical trial in 47 patients with vitiligo showed that the administration of GB 40 mg three times daily could halt disease progression and cause repigmentation of most perifacial vitiligo lesions [108]